Glenview Trust co Trims Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Glenview Trust co reduced its stake in shares of Boston Scientific Co. (NYSE:BSX) by 3.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 30,084 shares of the medical equipment provider’s stock after selling 1,001 shares during the period. Glenview Trust co’s holdings in Boston Scientific were worth $2,687,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Corient Private Wealth LLC boosted its position in shares of Boston Scientific by 1.2% in the fourth quarter. Corient Private Wealth LLC now owns 170,536 shares of the medical equipment provider’s stock worth $15,232,000 after purchasing an additional 2,097 shares during the period. Gitterman Wealth Management LLC boosted its holdings in Boston Scientific by 4.4% in the 4th quarter. Gitterman Wealth Management LLC now owns 3,959 shares of the medical equipment provider’s stock worth $354,000 after buying an additional 168 shares during the period. CBIZ Investment Advisory Services LLC increased its stake in Boston Scientific by 41.3% in the 4th quarter. CBIZ Investment Advisory Services LLC now owns 3,080 shares of the medical equipment provider’s stock worth $275,000 after buying an additional 900 shares in the last quarter. one8zero8 LLC bought a new stake in Boston Scientific during the fourth quarter valued at about $250,000. Finally, Choate Investment Advisors lifted its position in shares of Boston Scientific by 20.0% in the fourth quarter. Choate Investment Advisors now owns 4,084 shares of the medical equipment provider’s stock valued at $365,000 after acquiring an additional 680 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $97.26 on Monday. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $143.53 billion, a price-to-earnings ratio of 77.81, a PEG ratio of 2.79 and a beta of 0.77. Boston Scientific Co. has a 12 month low of $66.16 and a 12 month high of $107.17. The firm’s 50-day moving average is $101.05 and its 200 day moving average is $91.84.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Research analysts predict that Boston Scientific Co. will post 2.85 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on BSX. Piper Sandler increased their target price on Boston Scientific from $95.00 to $115.00 and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Argus set a $130.00 price objective on shares of Boston Scientific in a research report on Tuesday, February 18th. Morgan Stanley upped their target price on shares of Boston Scientific from $100.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Raymond James lifted their price target on shares of Boston Scientific from $119.00 to $122.00 and gave the company a “strong-buy” rating in a report on Thursday, February 6th. Finally, StockNews.com downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 8th. Two research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $108.91.

Insider Transactions at Boston Scientific

In other news, EVP Jeffrey B. Mirviss sold 4,675 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $104.25, for a total transaction of $487,368.75. Following the transaction, the executive vice president now directly owns 28,454 shares of the company’s stock, valued at approximately $2,966,329.50. This trade represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Daniel J. Brennan sold 67,333 shares of the business’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $105.24, for a total value of $7,086,124.92. Following the completion of the sale, the chief financial officer now owns 225,808 shares of the company’s stock, valued at $23,764,033.92. The trade was a 22.97 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 137,302 shares of company stock worth $14,319,269. Insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.